{"id":"https://openalex.org/W2038335142","doi":"https://doi.org/10.1111/j.1463-1326.2009.01073.x","title":"The effects of glucagon\u2010like peptide\u20101 on the beta cell","display_name":"The effects of glucagon\u2010like peptide\u20101 on the beta cell","alternate_titles":[],"publication_year":2009,"publication_date":"2009-10-29","ids":{"openalex":"https://openalex.org/W2038335142","doi":"https://doi.org/10.1111/j.1463-1326.2009.01073.x","mag":"2038335142","pmid":"https://pubmed.ncbi.nlm.nih.gov/19878257"},"language":"en","primary_location":{"id":"doi:10.1111/j.1463-1326.2009.01073.x","doi":"https://doi.org/10.1111/j.1463-1326.2009.01073.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2009.01073.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2038335142"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004120950","display_name":"Tina Vilsb\u00f8ll","orcid":"https://orcid.org/0000-0002-0456-6787","observed_orcids":["https://orcid.org/0000-0002-0456-6787"]},"institutions":[{"id":"https://openalex.org/I124055696","display_name":"University of Copenhagen","ror":"https://ror.org/035b05819","country_code":"DK","type":"education","lineage":["https://openalex.org/I124055696"]},{"id":"https://openalex.org/I2802582725","display_name":"Gentofte Hospital","ror":"https://ror.org/051dzw862","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802582725"]}],"countries":["DK"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"T. Vilsb\u00f8ll","raw_affiliation_strings":["Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. t.vilsboll@dadlnet.dk","Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. t.vilsboll@dadlnet.dk","institution_ids":["https://openalex.org/I124055696","https://openalex.org/I2802582725"]},{"raw_affiliation_string":"Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark","institution_ids":["https://openalex.org/I124055696","https://openalex.org/I2802582725"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5004120950"],"corresponding_institution_ids":["https://openalex.org/I124055696","https://openalex.org/I2802582725"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":1.2866,"has_fulltext":false,"cited_by_count":124,"citation_normalized_percentile":{"value":0.76076555,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":99},"biblio":{"volume":"11","issue":"s3","first_page":"11","last_page":"18"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9775000214576721,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9775000214576721,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10839","display_name":"Pancreatic function and diabetes","score":0.0215000007301569,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glucagon-like-peptide-1","display_name":"glucagon-like peptide-1","score":0.9990000128746033},{"id":"https://openalex.org/keywords/beta-cell-function","display_name":"beta-cell function","score":0.8820000290870667},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9959999918937683},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.8709999918937683},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.890999972820282},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.9919999837875366},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":1.0},{"id":"https://openalex.org/keywords/insulin-secretion","display_name":"insulin secretion","score":0.7239999771118164},{"id":"https://openalex.org/keywords/beta-cell-proliferation","display_name":"beta-cell proliferation","score":0.8270000219345093},{"id":"https://openalex.org/keywords/beta-cell-neogenesis","display_name":"beta-cell neogenesis","score":0.9539999961853027},{"id":"https://openalex.org/keywords/beta-cell-apoptosis","display_name":"beta-cell apoptosis","score":0.9879999756813049},{"id":"https://openalex.org/keywords/beta-cell-mass","display_name":"beta-cell mass","score":0.7829999923706055},{"id":"https://openalex.org/keywords/incretin-based-therapy","display_name":"incretin-based therapy","score":0.6000000238418579}],"concepts":[{"id":"https://openalex.org/C2776174256","wikidata":"https://www.wikidata.org/wiki/Q830842","display_name":"BETA (programming language)","level":2,"score":0.6474412679672241},{"id":"https://openalex.org/C2776828364","wikidata":"https://www.wikidata.org/wiki/Q1767180","display_name":"Beta cell","level":4,"score":0.5692648887634277},{"id":"https://openalex.org/C2778563252","wikidata":"https://www.wikidata.org/wiki/Q170617","display_name":"Glucagon","level":3,"score":0.5213802456855774},{"id":"https://openalex.org/C2779281246","wikidata":"https://www.wikidata.org/wiki/Q172847","display_name":"Peptide","level":2,"score":0.4971363842487335},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.449226051568985},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3459739685058594},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.33858823776245117},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.26727181673049927},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.26534342765808105},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2220800518989563},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.189546138048172},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.17309236526489258},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.1256222426891327},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.12092599272727966},{"id":"https://openalex.org/C165220095","wikidata":"https://www.wikidata.org/wiki/Q207524","display_name":"Islet","level":3,"score":0.06092861294746399},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077270","descriptor_name":"Exenatide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D050417","descriptor_name":"Insulin-Secreting Cells","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D050417","descriptor_name":"Insulin-Secreting Cells","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D054795","descriptor_name":"Incretins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1111/j.1463-1326.2009.01073.x","doi":"https://doi.org/10.1111/j.1463-1326.2009.01073.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2009.01073.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:19878257","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19878257","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Journal Article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/ef378260-7919-11df-928f-000ea68e967b","doi":null,"is_oa":false,"landing_page_url":"https://curis.ku.dk/portal/da/publications/the-effects-of-glucagonlike-peptide1-on-the-beta-cell(ef378260-7919-11df-928f-000ea68e967b).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306401983","display_name":"Research at the University of Copenhagen (University of Copenhagen)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I124055696","host_organization_name":"University of Copenhagen","host_organization_lineage":["https://openalex.org/I124055696"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vilsb\u00f8ll, T 2009, 'The effects of glucagon-like peptide-1 on the beta cell', Diabetes, Obesity and Metabolism, vol. 11 Suppl 3, pp. 11-18. https://doi.org/10.1111/j.1463-1326.2009.01073.x","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":53,"referenced_works":["https://openalex.org/W1012070930","https://openalex.org/W1532333918","https://openalex.org/W1916480346","https://openalex.org/W1983286754","https://openalex.org/W1984740259","https://openalex.org/W1986085856","https://openalex.org/W1986331352","https://openalex.org/W1988196562","https://openalex.org/W1994832750","https://openalex.org/W2001391476","https://openalex.org/W2004977380","https://openalex.org/W2013851956","https://openalex.org/W2019099090","https://openalex.org/W2024992738","https://openalex.org/W2031820400","https://openalex.org/W2039296612","https://openalex.org/W2043121816","https://openalex.org/W2063693981","https://openalex.org/W2067710447","https://openalex.org/W2068488844","https://openalex.org/W2071835038","https://openalex.org/W2074511950","https://openalex.org/W2082411535","https://openalex.org/W2093545531","https://openalex.org/W2098459806","https://openalex.org/W2101718966","https://openalex.org/W2102400698","https://openalex.org/W2103525547","https://openalex.org/W2104622496","https://openalex.org/W2106036385","https://openalex.org/W2113544353","https://openalex.org/W2118889627","https://openalex.org/W2127409471","https://openalex.org/W2132667679","https://openalex.org/W2137352234","https://openalex.org/W2138290933","https://openalex.org/W2145924144","https://openalex.org/W2146333376","https://openalex.org/W2146400000","https://openalex.org/W2149502431","https://openalex.org/W2153777416","https://openalex.org/W2156959752","https://openalex.org/W2159112515","https://openalex.org/W2159205789","https://openalex.org/W2159243532","https://openalex.org/W2159859567","https://openalex.org/W2160001758","https://openalex.org/W2162934281","https://openalex.org/W2166312550","https://openalex.org/W2167984392","https://openalex.org/W2170606300","https://openalex.org/W2752336761","https://openalex.org/W4388150965"],"related_works":["https://openalex.org/W124343605","https://openalex.org/W2024317462","https://openalex.org/W2125152775","https://openalex.org/W2550620500","https://openalex.org/W2153939828","https://openalex.org/W2066861619","https://openalex.org/W142502147","https://openalex.org/W3029835375","https://openalex.org/W24397505","https://openalex.org/W2021693796"],"abstract_inverted_index":{"Type":[0],"2":[1,29,78,127,213],"diabetes":[2],"is":[3,34,39,59],"a":[4],"progressive":[5],"disease":[6],"characterized":[7],"by":[8,62,131],"insulin":[9,44,139,152],"resistance":[10],"and":[11,92,97,136,143,150,154,170,183],"impaired":[12],"beta-cell":[13,19,121,159,175,178,181,185],"function.":[14],"Treatments":[15],"that":[16,38,105,167],"prevent":[17],"further":[18],"decline":[20],"are":[21,99,145,155,189],"therefore":[22],"essential":[23],"for":[24,73,208],"the":[25,68,74,111,209],"management":[26],"of":[27,71,76,83,101,114,198,211],"type":[28,77,126,212],"diabetes.":[30,79,214],"Glucagon-like":[31],"peptide-1":[32],"(GLP-1)":[33],"an":[35],"incretin":[36],"hormone":[37],"known":[40],"to":[41,49,109,147,157,161,191],"stimulate":[42,177],"glucose-dependent":[43],"secretion.":[45],"Furthermore,":[46],"GLP-1":[47,58,72,93,102],"appears":[48],"have":[50,86,106,118,165,204],"multiple":[51],"positive":[52],"effects":[53],"on":[54],"beta":[55],"cells.":[56],"However,":[57],"rapidly":[60],"degraded":[61],"dipeptidyl":[63],"peptidase-4":[64],"(DPP-4),":[65],"which":[66],"limits":[67],"clinical":[69,206],"relevance":[70],"treatment":[75,172,210],"Two":[80],"main":[81],"classes":[82],"GLP-1-based":[84],"therapies":[85],"now":[87],"been":[88,107],"developed:":[89],"DPP-4":[90],"inhibitors":[91],"receptor":[94,103],"agonists.":[95],"Liraglutide":[96],"exenatide":[98,144,171],"examples":[100],"agonists":[104],"developed":[108],"mimic":[110],"insulinotropic":[112],"characteristics":[113],"endogenous":[115],"GLP-1.":[116],"Both":[117],"demonstrated":[119],"improved":[120],"function":[122],"in":[123,195,201],"patients":[124],"with":[125],"diabetes,":[128],"as":[129],"assessed":[130],"homoeostasis":[132],"model":[133],"assessment-B":[134],"analysis":[135],"proinsulin":[137],":":[138],"ratio.":[140],"Additionally,":[141],"liraglutide":[142,169],"able":[146,156],"enhance":[148],"first-":[149],"second-phase":[151],"secretion":[153],"restore":[158],"sensitivity":[160],"glucose.":[162],"Preclinical":[163],"studies":[164,188],"shown":[166],"both":[168],"can":[173],"increase":[174,180],"mass,":[176],"proliferation,":[179],"neogenesis":[182],"inhibit":[184],"apoptosis.":[186],"Clinical":[187],"needed":[190],"confirm":[192],"these":[193,199],"findings":[194],"humans.":[196],"Replication":[197],"data":[200],"humans":[202],"could":[203],"important":[205],"implications":[207]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2038335142","counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":9},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":10},{"year":2014,"cited_by_count":9},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":9}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
